Immutep (NASDAQ:IMMP) Upgraded to Hold at Wall Street Zen

Immutep (NASDAQ:IMMP - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Thursday.

Immutep Trading Up 3.1%

IMMP traded up $0.06 during trading on Thursday, reaching $2.00. 107,966 shares of the company traded hands, compared to its average volume of 218,885. The company has a current ratio of 18.25, a quick ratio of 18.25 and a debt-to-equity ratio of 0.01. Immutep has a 12-month low of $1.32 and a 12-month high of $3.05. The firm has a fifty day simple moving average of $1.74 and a 200 day simple moving average of $1.90.

Institutional Investors Weigh In On Immutep

Hedge funds have recently made changes to their positions in the company. Fortitude Advisory Group L.L.C. bought a new position in shares of Immutep during the 4th quarter valued at approximately $28,000. XY Capital Ltd grew its position in Immutep by 52.0% in the fourth quarter. XY Capital Ltd now owns 164,655 shares of the biotechnology company's stock worth $357,000 after acquiring an additional 56,306 shares in the last quarter. ABC Arbitrage SA bought a new stake in Immutep during the fourth quarter worth approximately $152,000. OLD Mission Capital LLC purchased a new stake in Immutep during the fourth quarter valued at approximately $36,000. Finally, Two Sigma Securities LLC purchased a new stake in Immutep during the fourth quarter valued at approximately $74,000. 2.32% of the stock is currently owned by hedge funds and other institutional investors.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.